Knoll Capital Management LP has recently announced that it has increased stake in Applied Therapeutics Inc (NASDAQ:APLT) by 49.63%. After grabbing 5.16 million shares, the institutional investor is now in possession of 1.71 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 6.68% having worth around $10.89 million. Moreover, Propel Bio Management LLC increased its share by 4.76 million to have a control over 4.76 million shares. And Perceptive Advisors LLC raised its holdings to 4.08 million shares by acquiring 4.08 million shares or 5.28% of the stake.
Applied Therapeutics Inc (APLT) concluded trading on 01/04/24 at a closing price of $3.79, with 3.57 million shares of worth about $13.54 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 193.80% during that period and on Thursday the price saw a gain of about 5.57%. Currently the company’s common shares owned by public are about 77.23M shares, out of which, 54.45M shares are available for trading.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 21 times over the past 12 months. They bought 4,526,737 shares in 10 of the transactions. In 11 selling transactions, insiders dumped 2,337,702 shares.
FTIF SICAV – Biotechnology Discov, Franklin Biotechnology Discovery, and Fidelity Select Port. – Biotechno are the top 3 mutual funds which are holding stakes in Applied Therapeutics Inc FTIF SICAV – Biotechnology Discov is currently holding 10.37 million shares of worth totaling $21.89 million. The company recently came selling 46700.0 shares which brought its stake up to 13.43% of the company’s outstanding shares. Franklin Biotechnology Discovery sold 29615.0 shares, after which its hold over company’s outstanding shares shrunk to 6.47%, leaving 5.0 million shares with the mutual fund that have a worth of about $10.54 million. Fidelity Select Port. – Biotechno, after buying 2.64 million shares, have now control over 3.42% of the stake in the company. It holds 0.0 shares of worth $5.57 million.
Applied Therapeutics Inc (NASDAQ: APLT) started trading at $3.56, below -$0.03 from concluding price of the previous day. However, the stock later moved at a day high price of 3.8600, or with a gain of 5.57%. Stock saw a price change of 20.70% in past 5 days and over the past one month there was a price change of 51.60%. Year-to-date (YTD), APLT shares are showing a performance of 13.13% which increased to 403.86% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.76 but also hit the highest price of $4.42 during that period. The average intraday trading volume for Applied Therapeutics Inc shares is 1.05 million. The stock is currently trading 25.52% above its 20-day simple moving average (SMA20), while that difference is up 48.49% for SMA50 and it goes to 111.37% higher than SMA200.
Knoll Capital Management LP acquired 5.16 million shares of Applied Therapeutics Inc having value of about $10.89 million. Data submitted at the U.S SEC by Knoll Capital Management LP revealed that the firm now holds 1.71 million shares in the company valued at close to $6488813.52, or have control over 49.63% stake in the company. Applied Therapeutics Inc (NASDAQ: APLT) currently have 77.23M outstanding shares and institutions hold larger chunk of about 59.66% of that. Holding of mutual funds in the company is about 29.14% while other institutional holders and individual stake holders have control over 30.52% and 21.36% of the stake respectively.
The stock has a current market capitalization of $292.70M and its 3Y-monthly beta is at 1.52. It has posted earnings per share of -$1.32 in the same period. It has Quick Ratio of 0.80. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for APLT, volatility over the week remained 17.40% while standing at 13.32% over the month.
Analysts are in expectations that Applied Therapeutics Inc (APLT) stock would likely to be making an EPS of -$0.27 in the current quarter, while forecast for next quarter EPS is -$0.22 and it is -$0.96 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.32 which is -$0.17 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.16 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 29.67% while it is estimated to increase by 45.30% in next year.
Analysts at 2 brokerage firms have issued recommendations for the Applied Therapeutics Inc (APLT)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.50. Out of those 2 Wall Street analysts, 1 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Barclays on January 04, 2022 offering an Equal weight rating for the stock and assigned a target price range of between $44 and $7 to it.
